Schroder Investment Management Group Has $64.64 Million Stock Holdings in Exact Sciences Corporation $EXAS

Key Points

• Schroder Investment Management Group raised its stake in Exact Sciences by 49.3% in Q3 to 1,210,865 shares, worth about $64.64 million and representing roughly 0.64% of the company.
• Exact Sciences recently reported a quarterly loss of $0.21 EPS (missing the $0.08 estimate) while revenue rose 23.1% year-over-year, and analysts forecast a full-year EPS of about -0.58.
• The stock is trading near its 12-month high (opened at $103.37) with a market cap of about $19.7 billion, and Wall Street's consensus rating is "Reduce" with a $92.13 target (21 Holds, 1 Sell).

Schroder Investment Management Group grew its holdings in Exact Sciences Corporation (NASDAQ:EXAS - Free Report) by 49.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,210,865 shares of the medical research company's stock after purchasing an additional 399,665 shares during the period. Schroder Investment Management Group owned approximately 0.64% of Exact Sciences worth $64,636,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of EXAS. Great Lakes Advisors LLC lifted its position in shares of Exact Sciences by 3.7% during the 1st quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company's stock worth $215,000 after buying an additional 178 shares during the last quarter. Capital Asset Advisory Services LLC grew its position in Exact Sciences by 4.8% in the third quarter. Capital Asset Advisory Services LLC now owns 3,941 shares of the medical research company's stock valued at $216,000 after acquiring an additional 182 shares during the last quarter. Assetmark Inc. raised its stake in Exact Sciences by 7.2% during the third quarter. Assetmark Inc. now owns 3,588 shares of the medical research company's stock worth $196,000 after acquiring an additional 242 shares in the last quarter. Westside Investment Management Inc. raised its stake in Exact Sciences by 100.0% during the third quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company's stock worth $31,000 after acquiring an additional 271 shares in the last quarter. Finally, Clearstead Advisors LLC lifted its holdings in shares of Exact Sciences by 11.7% in the third quarter. Clearstead Advisors LLC now owns 3,472 shares of the medical research company's stock worth $190,000 after acquiring an additional 365 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.

Exact Sciences Stock Performance

Shares of EXAS stock opened at $103.37 on Wednesday. The business's 50-day moving average price is $102.72 and its 200-day moving average price is $82.91. Exact Sciences Corporation has a 12 month low of $38.81 and a 12 month high of $103.75. The firm has a market capitalization of $19.73 billion, a price-to-earnings ratio of -93.97, a PEG ratio of 2.36 and a beta of 1.41. The company has a current ratio of 2.43, a quick ratio of 2.17 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. The firm's quarterly revenue was up 23.1% compared to the same quarter last year. During the same period last year, the company posted ($0.06) earnings per share. Equities research analysts forecast that Exact Sciences Corporation will post -0.58 EPS for the current year.

Wall Street Analysts Forecast Growth

EXAS has been the topic of a number of research analyst reports. Mizuho restated a "neutral" rating and issued a $105.00 price target (up from $85.00) on shares of Exact Sciences in a research note on Tuesday, January 20th. Craig Hallum cut shares of Exact Sciences from a "buy" rating to a "hold" rating and set a $105.00 price objective for the company. in a research report on Friday, November 21st. Evercore set a $105.00 price objective on shares of Exact Sciences and gave the company an "in-line" rating in a research note on Monday, January 5th. BTIG Research lowered shares of Exact Sciences from a "buy" rating to a "neutral" rating in a research report on Thursday, November 20th. Finally, Benchmark cut shares of Exact Sciences from a "buy" rating to a "hold" rating in a research note on Monday, November 24th. Twenty-one equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Reduce" and a consensus target price of $92.13.

About Exact Sciences

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company's flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.